Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas
Open Access
- 1 September 2020
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (9) , 3015-3024
Abstract
Aim Reduced calcium sensing receptor (CaSR) expression has been implicated in parathyroid tumorigenesis, but the underlying mechanism remains elusive. Accordingly, we aimed to explore the epigenetic changes (DNA methylation and histone modifications) involved in CaSR regulation in sporadic parathyroid adenomas and correlate epigenetic state with disease indices. Experimental Design Forty sporadic parathyroid adenomas and 10 control parathyroid tissues were studied. Real-time quantitative PCR (qPCR) for mRNA and immunohistochemistry for protein expression of CaSR were performed. The methylation status of the CaSR promoter 2 was determined by bisulphite sequencing analysis of sodium bisulphite-converted DNA. To determine the role of histone modifications in the CaSR regulation, chromatin immunoprecipitation-qPCR assay was performed. Results Real-time qPCR revealed reduced CaSR mRNA expression with a fold reduction of 0.12 (P < 0.0001) in parathyroid adenomas. Immunohistochemistry revealed reduced protein expression of CaSR in 90% (36/40) of adenomas. The promoter 2 region of CaSR displayed significant hypermethylation in 45% (18/40) of the adenomas compared with the controls (6.7%; 1 of 10) (P < 0.002). Bisulphite sequencing analysis revealed maximum methylated CpG at glial cell missing 2 binding site on the CaSR promoter 2 compared to other CpG sites. The methylation status of CaSR correlated directly with plasma intact parathyroid hormone levels in patients with parathyroid adenoma. With chromatin immunoprecipitation-qPCR analysis, H3K9me3 levels showed increased enrichment by 10-fold in adenomas and correlated with CaSR-mRNA expression (r = 0.61; P < 0.003). Treatment with 5-aza-2′deoxycytidine restored the expression of CaSR in a parathyroid cell line. Conclusion Our data suggest that hypermethylation and increased H3K9me3 of the CaSR promoter 2 are involved in silencing CaSR expression in sporadic parathyroid adenoma.Keywords
Funding Information
- Indian Council of Medical Research (3/1/3-JRF2014/HRD-57)
- Department of Science and Technology, New Delhi (EMR/2016/005956)
- Postgraduate Institute of Medical Education and Research (71/8-Edu-15/2544)
- National Institutes of Health (DK43858)
This publication has 37 references indexed in Scilit:
- Calcium sensing receptor signalling in physiology and cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
- Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persistsBMC Cancer, 2010
- Frequent Promoter Hypermethylation of the APC and RASSF1A Tumour Suppressors in Parathyroid TumoursPLOS ONE, 2010
- The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretionAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- A glimpse into the epigenetic landscape of gene regulationCurrent Opinion in Genetics & Development, 2008
- Epigenetic gene silencing in cancer: the DNA hypermethylomeHuman Molecular Genetics, 2007
- Chromatin remodeling, histone modifications, and DNA methylation—how does it all fit together?Journal of Cellular Biochemistry, 2002
- Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic miceJournal of Clinical Investigation, 2001
- Reduced vitamin D receptor expression in parathyroid adenomas: implications for pathogenesisClinical Endocrinology, 2000
- No Evidence for Mutations in the Calcium-Sensing Receptor Gene in Sporadic Parathyroid AdenomasJournal of Bone and Mineral Research, 1999